Ovarian Cancer Clinical Trials

145 studies are recruiting for ovarian cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer

   Ascites samples from women undergoing surgery for ovarian cancer will be collected for use in translational research.

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of New Mexico Cancer Center, Albuquerque, New Mexico

   Run by

   New Mexico Cancer Research Alliance

   See if you can join NCT03943316 on ClinicalTrials.gov

2. Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

   This trial studies how well fecal microbiota transplantation works in treating diarrhea or colitis (inflammation of the intestines) that is caused by certain types of medications (called immune-checkpoint inhibitors) in patients with genitourinary cancer. Fecal microbiota transplantation may effect…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04038619 on ClinicalTrials.gov

3. BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

   The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed after standard therapy. The main questions it aims to answer are: * how safe and tolerable is BI-1…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope National Medical Center, Duarte, California

   Locations

   25 in total

   Run by

   BioInvent International AB

   See if you can join NCT04752826 on ClinicalTrials.gov

4. Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

   The purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning chemotherapy, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Moffitt Cancer Center, Tampa, Florida

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT05316129 on ClinicalTrials.gov

5. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   City of Hope, Duarte, California

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

6. A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

   Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is us…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Alabama - Birmingham ( Site 0058), Birmingham, Alabama

   Locations

   163 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07318558 on ClinicalTrials.gov

7. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Colorado Denver, Aurora, Colorado

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

8. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   University of San Diego Moores Cancer Center, La Jolla, California

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

9. Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

   This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   OU Health, Stephenson Cancer Center, Oklahoma City, Oklahoma

   Locations

   4 in total

   Run by

   Imunon

   See if you can join NCT05739981 on ClinicalTrials.gov

10. Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

    This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Advent Health, Orlando, Florida

    Locations

    9 in total

    Run by

    Imunon

    See if you can join NCT06915025 on ClinicalTrials.gov

11. A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.

    Stage

    Phase 2

    Ages

    18 to 99

    Site

    Usa Health Mitchell Cancer Institute, Mobile, Alabama

    Locations

    74 in total

    Run by

    Incyte Corporation

    See if you can join NCT07023627 on ClinicalTrials.gov

12. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

    The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Valkyrie Clinical Trials, Los Angeles, California

    Locations

    192 in total

    Run by

    Incyte Corporation

    See if you can join NCT07214779 on ClinicalTrials.gov

13. A Study of Isoquercetin in People With Ovarian Cancer

    The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

    Locations

    8 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT07303894 on ClinicalTrials.gov

14. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

    The purpose of this multicenter, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in participants with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjuga…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Alabama, Birmingham, Alabama

    Locations

    29 in total

    Run by

    Tubulis GmbH

    See if you can join NCT06303505 on ClinicalTrials.gov

15. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

    This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    The University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    56 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06787612 on ClinicalTrials.gov

16. A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

    This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours alone or in combination with anti-cancer agents

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Santa Monica, California

    Locations

    67 in total

    Run by

    AstraZeneca

    See if you can join NCT05123482 on ClinicalTrials.gov

17. DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

    The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting ch…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts

    Locations

    3 in total

    Run by

    Elizabeth Stover, MD, PhD

    See if you can join NCT06964009 on ClinicalTrials.gov

18. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama Birmingham, Birmingham, Alabama

    Locations

    26 in total

    Run by

    SystImmune Inc.

    See if you can join NCT06293898 on ClinicalTrials.gov

19. Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

    This is a single site, open label, Phase 1 study using a 3 + 3 dose escalation design in two cohorts of adults with recurrent, platinum-resistant ovarian tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06646627 on ClinicalTrials.gov

20. Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

    This Phase 3 study will be conducted in different countries around the world with up to about 544 participants. The purpose of this study is to evaluate how well Rina-S works against ovarian cancer in combination with available standard of care therapy that is already approved and used for ovarian …

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Mt. Sinai Comprehensive Cancer Center, Miami, Florida

    Locations

    22 in total

    Run by

    Genmab

    See if you can join NCT07225270 on ClinicalTrials.gov

21. Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence

    The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence. The main question[s] it aims to answer [is/are]: Does psilocybin assisted therapy improve fear of cancer recurrenc…

    Stage

    Phase 1

    Ages

    21 and older

    Site

    Outpatient CTRC, Aurora, Colorado

    Locations

    2 in total

    Run by

    University of Colorado, Denver

    See if you can join NCT06430541 on ClinicalTrials.gov

22. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope National Medical Center, Duarte, California

    Locations

    39 in total

    Run by

    Eli Lilly and Company

    See if you can join NCT06465069 on ClinicalTrials.gov

23. Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

    Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Desi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Banner Health, Gilbert, Arizona

    Locations

    16 in total

    Run by

    A2 Biotherapeutics Inc.

    See if you can join NCT04981119 on ClinicalTrials.gov

24. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

    The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Alabama at Birmingham ( Site 0006), Birmingham, Alabama

    Locations

    196 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06824467 on ClinicalTrials.gov

25. Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.

    This is a Phase 1 study to assess safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in advanced or metastatic ovarian or endometrial cancer.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida

    Locations

    6 in total

    Run by

    ArriVent BioPharma, Inc.

    See if you can join NCT07755436 on ClinicalTrials.gov